From: Searching for the true genetic vulnerability for schizophrenia
Study | Number of subjects | Geographical locations | Laboratory methods | Results |
---|---|---|---|---|
Stefansson et al. [21] | 1,433 patients with schizophrenia; 33,250 controls. Follow-up with 3,285 cases and 7,951 controls | England, Finland, Germany, Iceland, Italy and Scotland | High-density SNP microarrays | Deletions at chromosomes 1q21.1, 15q11.2 and 15q13.3 associated with schizophrenia (findings in bold are those that are present in more than 1 study) |
The International Schizophrenia Consortium [22]* | 3,391 patients with schizophrenia (according to the DSM-IV or ICD-10 definitions†); 3,181 ancestrally matched controls | Several sites: Bulgaria, England, Ireland, Portugal (Azores), Scotland and Sweden | High-density SNP microarrays | 1.15× increase in schizophrenia for CNVs greater than 100 kb and in less than 5% of the sample. Deletions found in the VCSF region on chromosome 22, ad in chromosomes 15q13.3 and 1q21.1 |
Walsh et al. [20] | 150 patients with schizophrenia; 268 ancestrally matched controls | USA (various locations) | CGH screen (85,000 probe arrays initially, and an Illumina 550 array for validation to identify microdeletions greater than 100 kb) | Novel deletions and duplications present in 15% of adult and 20% of COS patients versus 5% of controls. No one of these specifically associated with schizophrenia. In COS deletions in 2q31.2, 2p16.3 (NRXN1 gene), 16p11.2 were associated |
Sutrala et al. [23]* | 85 unrelated Caucasians with schizophrenia (DSM-IV definition); control DNA was from the CEPH†collection | England and Ireland | CGH screen with oligonucleotide probes of 891 candidate genes, then allele quantification by DNA pooling for 15 genes | CGH screen yielded CNVs in six genes, but no excess in schizophrenia. No CNV was found by either method to be in excess in schizophrenia |